Advancements in the battle against severe acute respiratory syndrome
Publication in refereed journal


Times Cited
Web of Science10WOS source URL (as at 18/10/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractSevere acute respiratory syndrome (SARS) is a newly emerged infectious disease with a significant morbidity and mortality. The major clinical features include persistent fever, chills/rigor, myalgia, malaise, dry cough, headache and dyspnoea. Respiratory failure is the major complication of SARS and similar to 20% of patients may progress to acute respiratory distress syndrome requiring invasive mechanical ventilatory support. However, the severity is much milder in infected young children. Treatment of SARS was empirical in 2003 due to our limited understanding of this new disease. Protease inhibitors (lopinavir/ritonavir) in combination with ribavirin may play a role as antiviral therapy in the early phase, whereas the role of IFN and systemic steroid in preventing immune-mediated lung injury deserves further investigation. Knowledge of the genomic sequence of the SARS coronavirus has facilitated the development of rapid diagnostic tests. In addition, other antiviral treatment, RNA interference, monoclonal antibody, synthetic peptides, and vaccines are being developed. This paper provides a review of the epidemiology, clinical features and possible treatment strategies of SARS.
All Author(s) ListHui DSC, Wong GWK
Journal nameExpert Opinion on Pharmacotherapy
Year2004
Month8
Day1
Volume Number5
Issue Number8
PublisherASHLEY PUBLICATIONS LTD
Pages1687 - 1693
ISSN1465-6566
eISSN1744-7666
LanguagesEnglish-United Kingdom
Keywordsclinical features; epidemiology; pharmacotherapy; SARS
Web of Science Subject CategoriesPharmacology & Pharmacy; PHARMACOLOGY & PHARMACY

Last updated on 2020-19-10 at 02:31